Adjuvant Carboplatin Plus Paclitaxel for Stage III Triple-Negative Breast Cancer
For stage III triple-negative breast cancer, you should use pembrolizumab-based chemoimmunotherapy (carboplatin + paclitaxel followed by anthracycline/cyclophosphamide) as the preferred postoperative regimen, not carboplatin-paclitaxel alone. 1
Primary Recommendation: Pembrolizumab-Based Regimen
The NCCN 2025 guidelines designate pembrolizumab + carboplatin + paclitaxel followed by anthracycline-based chemotherapy as Category 1 (highest level of evidence) for stage II-III TNBC 1. This is based on the KEYNOTE-522 trial, which demonstrated superior pathological complete response (pCR 65% vs 51%), event-free survival, and overall survival benefits.
The specific regimen is:
- Preoperative: Pembrolizumab + carboplatin + paclitaxel
- Followed by: Pembrolizumab + cyclophosphamide + doxorubicin or epirubicin
- Then: Adjuvant pembrolizumab maintenance 1
This represents the current standard of care for stage III TNBC, not carboplatin-paclitaxel alone.
If Carboplatin-Paclitaxel Without Immunotherapy Is Being Considered
If pembrolizumab is contraindicated or unavailable, the evidence for adding carboplatin to standard anthracycline-taxane chemotherapy shows:
Survival Benefits
The most recent high-quality evidence from the CITRINE trial (2025) demonstrated that adding carboplatin to epirubicin/cyclophosphamide followed by weekly paclitaxel significantly improved outcomes in high-risk early TNBC 2:
- 3-year disease-free survival: 92.3% vs 85.8% (HR 0.64, p=0.03)
- 3-year overall survival: 98.0% vs 94.0% (HR 0.41, p=0.01)
- 3-year distant disease-free survival: 94.8% vs 89.8% (HR 0.61, p=0.04)
Critical caveat: The proportional hazards assumption was violated (p=0.02), meaning the benefit changed over time. The hazard ratio was strongest in the first 12 months (HR 0.31), diminished at 12-36 months (HR 0.65), and reversed after 36 months (HR 1.98) 2. This suggests carboplatin primarily reduces early recurrence risk but may not provide sustained long-term benefit.
Menopausal Status Matters
A 2026 phase III trial showed significant interaction between carboplatin benefit and menopausal status 3:
- Premenopausal patients: Significant benefit with 5-year EFS 75.0% vs 59.6% (HR 0.61, p=0.003) and OS 78.2% vs 64.6% (HR 0.57, p=0.002)
- Postmenopausal patients: No significant benefit for EFS (HR 1.19, p=0.386) or OS (HR 1.06, p=0.772)
This means carboplatin should be strongly considered in premenopausal stage III TNBC patients but may not benefit postmenopausal patients.
Toxicity Considerations
Adding carboplatin increases hematological toxicity 2, 4:
- Grade 3-4 adverse events: 66.7% vs 55.0%
- Increased anemia, neutropenia, and thrombocytopenia
- Higher rates of dose reduction and treatment discontinuation
- However, no treatment-related deaths occurred 2
The toxicity is generally manageable with supportive care, and the survival benefits in appropriate patients outweigh these risks.
Clinical Algorithm
For stage III TNBC patients:
First choice: Pembrolizumab + carboplatin + paclitaxel → anthracycline regimen (KEYNOTE-522 protocol) 1
If pembrolizumab contraindicated/unavailable:
- Premenopausal patients: Add carboplatin to anthracycline-taxane backbone (strong evidence of benefit) 3
- Postmenopausal patients: Consider standard anthracycline-taxane without carboplatin (limited evidence of carboplatin benefit) 3
- High-risk features (node-positive, Ki-67 ≥50%): Consider carboplatin addition regardless of menopausal status 2
Acceptable alternative regimen: Dose-dense AC followed by weekly paclitaxel (without carboplatin) remains evidence-based 1
Important Pitfalls
- Do not use carboplatin-paclitaxel alone without anthracyclines for stage III disease—this lacks adequate evidence
- Do not assume carboplatin benefits all TNBC patients equally—menopausal status and timing of benefit matter
- Do not overlook the ESMO 2024 guideline which emphasizes taxane-carboplatin as an evidence-based backbone but in the context of HER2-positive disease, not as standalone for TNBC 5
- The benefit of carboplatin appears strongest in preventing early recurrence (0-12 months), not late recurrence 2